Observational studyCancer prevention research (Philadelphia, Pa.)2015
NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project.
Observational study in Cancer prevention research (Philadelphia, Pa.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- The relationship between aspirin consumption and hepatocellular carcinoma: a systematic review and meta-analysis.European journal of medical research · 2023Pooled it
- Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin.Alimentary pharmacology & therapeutics · 2023Pooled it
- Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies.BMC cancer · 2018Pooled it
- Aspirin on the prevention of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on "Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Nationwide cohort study with genetic risk analysis".Clinical and molecular hepatology · 2026Article
- Chemoprevention of hepatocellular carcinoma.Hepatology communications · 2025Review
- Review
- Gemcitabine and Flurbiprofen Enhance Cytotoxic Effects on Cancer Cell Lines Mediated by Mesenchymal Stem Cells.International journal of molecular sciences · 2025Article
- Association between antithrombotic agents use and hepatocellular carcinoma risk: a two-sample mendelian randomization analysis.Journal of cancer research and clinical oncology · 2024Article
- Diet, lifestyle factors, comorbidities, and hepatocellular carcinoma risk in a middle eastern country: a case-control study.BMC cancer · 2024Article
- Peripheral blood platelet counts identify prognostically diverse clinical phenotypes in hepatocellular carcinoma.Annals of gastroenterology and the digestive system · 2024Article
- The exposome and liver disease - how environmental factors affect liver health.Journal of hepatology · 2023Review
- The Effect of Aspirin Use on Incident Hepatocellular Carcinoma-An Updated Systematic Review and Meta-Analysis.Cancers · 2023Review
- Impact of Aspirin Use on Outcomes in Patients With Hepatocellular Cancer: A Nationwide Analysis.World journal of oncology · 2023Article
- The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma.European journal of clinical investigation · 2023Article
- Efficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysis.Journal of clinical and translational hepatology · 2022Article
- Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?Clinical and molecular hepatology · 2022Review
- Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases.Clinical and molecular hepatology · 2022Review
- Aspirin, Statins, Non-aspirin NSAIDs, Metformin, and the Risk of Biliary Cancer: A Swedish Population-Based Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Review
- Oral Cyanobacteria and Hepatocellular Carcinoma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
30 authors at 2 institutions in 1 country.
Funding
Abstract
Chronic inflammation plays a pivotal role in the pathogenesis of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), the two most common types of liver cancer. A number of prior experimental studies have suggested that nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin and ibuprofen, may potentially protect against liver cancer. However, no observational study has examined the association between aspirin duration and dose or other over-the-counter non-aspirin NSAIDs, such as ibuprofen, and liver cancer incidence. Furthermore, the association between NSAID use and risk of ICC is unclear. As part of the Liver Cancer Pooling Project, we harmonized data on 1,084,133 individuals (HCC = 679, ICC = 225) from 10 U.S.-based prospective cohort studies. Cox proportional hazards regression models were used to evaluate multivariable-adjusted HRs and 95% confidence intervals (CI). Current aspirin use, versus nonuse, was inversely associated with HCC (HR, 0.68; 95% CI, 0.57-0.81), which persisted when restricted to individuals not using non-aspirin NSAIDs and in a 5- and 10-year lag analysis. The association between aspirin use and HCC risk was stronger for users who reported daily use, longer duration use, and lower dosage. Ibuprofen use was not associated with HCC risk. Aspirin use was associated with a reduced ICC risk in men (HR, 0.64; 95% CI, 0.42-0.98) but not women (HR, 1.34; 95% CI, 0.89-2.01; P(interaction) = 0.01). The observed inverse association between aspirin use and liver cancer in our study, together with previous data, suggests the merit of future intervention studies of aspirin and other agents that affect chronic inflammatory pathways for HCC and possibly ICC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.